Panitumumab
Panitumumab
Immunoglobulin, anti-(human epidermal growth factor receptor) (human monoclonal ABX-EGF heavy chain), disulfide with human monoclonal ABX-EGF light chain, dimer
Stoffgruppe
Antineoplastisches Mittel (EGFR-Inhibitor)
Halbwertszeit
3,6-10,9 Tage
Präparate